Expanded suite to unify sales, marketing, medical and service through a connected software and data foundation SINGAPORE, Sept. 5, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva Vault CRM Service Center for inside sales, contact center, and hybrid reps in APAC. Supporting inbound and outbound engagement across channels, Vault CRM Service Center enables life sciences companies to eliminate siloes among...Read more
New capabilities and simple, standard site experience cut trial time and expense Fixed price implementation to get up and running quickly Industry advances to connected trials as seven of the top 20 biopharmas adopt Veeva Site Connect PLEASANTON, Calif., Sept. 5, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced, in a major step forward for clinical trial execution, the newest release of Veeva Site Connect, adding...Read more
Estimated to save individual Accredo patients around $4,000 per year Biosimilar price will be more than 80% lower than Stelara list price Accredo patients benefit from the specialty pharmacy's best-in-class clinical support BLOOMFIELD, Conn., Sept. 5, 2024 /PRNewswire/ -- Evernorth Health Services announced that it plans to have a Stelara biosimilar available for $0 out of pocket for eligible patients of its specialty...Read more
Total Revenues of $676.2M, up 15% Year Over Year; Subscription Services Revenues of $561.3M, up 19% Year Over Year PLEASANTON, Calif., Aug. 28, 2024 /PRNewswire/ -- Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its second quarter ended July 31, 2024. "It was another quarter of great execution, with major product advances in...Read more
Life sciences organizations now manage all quality control data and processes in one solution for greater efficiency and speed PLEASANTON, Calif., Aug. 22, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced increasing momentum for Veeva Vault LIMS, a modern cloud solution that simplifies end-to-end quality control (QC) business processes. Vault LIMS is unified with Veeva Vault Quality, enabling customers to share...Read more
Published in Anesthesia and Analgesia, results from the multi-site trial evaluating End-tidal Control software provide compelling evidence for enhanced accuracy and efficiency of anesthesia delivery compared to conventional anesthetic gas delivery methods.1 End-tidal Control is the first FDA-approved software that automatically adjusts and maintains exhaled oxygen and exhaled anesthetic concentrations, with more accuracy in reaching the...Read more
Total revenues for the second quarter 2024 increased 25% to $60.5 billion Shareholders' net income for the second quarter 2024 was $1.5 billion, or $5.45 per share Adjusted income from operations1 for the second quarter 2024 was $1.9 billion, or $6.72 per share 2024 outlook2 for adjusted income from operations1,2 is at least $28.40 per share BLOOMFIELD, Conn., Aug. 1, 2024 /PRNewswire/ -- Global health company The Cigna Group...Read more
Revenues were flat year-over-year; Organic revenue growth* was 1% Net income margin was 8.9% versus 8.7% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 15.3% versus 14.8% Diluted earnings per share (EPS) were $0.93 versus $0.91 for the prior year; Adjusted EPS* was $1.00 versus $0.92 Cash flow from operating activities was $(119) million versus $(67) million for the prior year; Free cash flow* was...Read more
New Veeva Pulse findings show congresses and early-career experts have the strongest influence on patient outcomes PLEASANTON, Calif., July 25, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today revealed that targeted pre-launch scientific outreach maximizes medical affairs teams' impact on treatment adoption in the latest Veeva Pulse Field Trends Report. The analysis shows biopharmas investing in pre-launch scientific activities...Read more
GE HealthCare selects AWS as its strategic cloud provider to deliver entirely new, purpose-built foundation models designed to fast-track the development of innovative healthcare applications GE HealthCare plans to train and deploy clinical foundation models on AWS’s machine learning and generative AI technologies to help healthcare providers expedite clinical and operational workflows to improve delivery of care CHICAGO / Jul 25,...Read more
Raises 2024 Guidance NASHVILLE, Tenn. / Jul 23, 2024 / Business Wire / HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the second quarter ended June 30, 2024. Key second quarter metrics (all percentage changes compare 2Q 2024 to 2Q 2023 unless otherwise noted): Revenues totaled $17.492 billion Net income attributable to HCA Healthcare, Inc. totaled $1.461 billion, or $5.53 per diluted...Read more
Agreement to acquire business adds innovative, real-time image recognition technology and expertise to GE HealthCare’s portfolio of AI-enabled devices AI-based technology from Intelligent Ultrasound aims to provide real-time support for OBGYN scans and improve exam accuracy and efficiency Planned acquisition supports GE HealthCare’s precision care strategy to address inefficiencies and improve patient care quality CHICAGO / Jul 18,...Read more
2Q 2024 operating revenue of $43.2 billion 2Q 2024 adjusted operating gain1 of $2.8 billion 2Q 2024 diluted EPS2 of $9.85, up 26%; adjusted diluted EPS1 of $10.12, up 12% 3Q 2024 dividend of $1.63 per share declared to shareholders INDIANAPOLIS / Jul 17, 2024 / Business Wire / Elevance Health, Inc. (NYSE: ELV) reported second quarter 2024 results. “Second quarter results reflect the power of our diversified business and thoughtful...Read more
Revenues of $98.9 Billion Grew Nearly $6 Billion Year Over Year, Led by Optum Consumers Served by UnitedHealthcare’s Commercial Domestic Offerings Grew 2.3 Million Year to Date Cash Flows from Operations were $6.7 Billion or 1.5x Net Income Second Quarter Earnings of $4.54 Per Share Reflect Classification of Remaining South American Operations as Held for Sale and Cyberattack Impacts Adjusted Earnings of $6.80 Per Share Include $0.28...Read more
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE